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The antibody cross match in liver 
transplantation 
Robert D. Gordon, M.D., John J. Fung, M.D., Ph.D., Bernd Markus, M.D., Ira Fox, M.D., 
Shunzaburo lwatsuki, M.D., Carlos O. Esquivel, M.D., Ph.D., Andrus Tzakis, M.D., 
Satoru Todo, M.D., and Thomas E. Stanl, M.D., Ph.D., Pittsburgh, Pa. 
Six hundred sixty-seven first, second, and third orthotopic liver allografts in 520 
patients were reviewed to determine the effect of recipient panel-reactive antibody 
(PRA) and donor-recipient antibody crossmatch on 2-year patient and liver allograft 
survival rates. Neither a high panel-reactive antibody nor a positive crossmatch for 
donor-specific preformed antIbody was associated with decreased patIent or liver 
allograft survival for primary grafts or retransplants. Two patients have been given 
kidney transplants immediately after a liver allograft from a donor WIth whom each 
patient had an initial strongly poSitive donor-specific antibody crossmatch. The liver 
apparently removed or neutralized circulating anti-donor antibody, since the renal 
allografts functioned promptly and did not experience hyperacute rejection. 
From the Department of Surgery, L/niuernly lIealth Center of Pittsburgh, L'nlUernty of 
PittsburfJh, and the Veterans AdminIStration Medical Center, Pittsburgh, Pa. 
TRANSPLANTATION Of RENAL allografts in the presence of 
preformed antibody to human leukocyte (HLA)-
antigens on donor lymphocytes is associated with a 
high incidence of hyperacute allograft rejection. I·' Fur-
thermore, transplantation of a renal allograft from a 
crossmatch-negative donor into a recipient with a high 
percentage of panel-reactive antibody (PRA) at the 
time of transplantation is associated with decreased 
graft survivaL I 
We have previously reponed that transplantation of 
the liver in the presence of preformed antidonor 
antibody is associated with neither hyperacute rejection 
of the liver nor with decreased graft survival. 0.7 Our 
last repon was based on an analysis of I-year graft 
survival rates for 134 recipients of 174 liver trans-
plants. We now have accumulated experience with 520 
recipients of 667 grafts. In this anicle, the relationship 
between antibody crossmatch and recipient PRA at the 
time of transplantation and 2-year graft survival rates 
are examined once more. 
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MATERIAL AND METIIODS 
CUe material. Six hundred sixty-seven liver grafts 
in 520 patients performed ~tween March 1, 1980 and 
Dec. 31, 1985 with cyclosporine-prednisone are includ-
ed in this study. Three primary grafts done before 
March 1, 1980 with azathioprine and steroids are not 
included. One surviving patient has received a fourth 
transplant that is also not included. Thus this review is 
based on 517 primary grafts, 123 second grafts, and 27 
third grafts. 
All patients have been followed through Jan. 31, 
1986. Actuarial patient and graft survival were calcu-
lated by the life table method." 9 The age range of the 
patients was 4 months to 67 years (mean 25.3 ± 18.1, 
SO years) including 310 adults given 385 grafts and 
210 children given 282 grafts. 
All patients were treated with cyclosporine-predni-
sone.1O Since December 1984, OKT3 monoclonal anti-
body (Onho Pharmaceuticals, Raritan, N.].) has been 
given for brief periods (\0 to 21 days) to about 75 
patients for treatment of acute cellular rejection or 
during periods of reduced cyclosporine coverage. I I 
The most common primary indications for liver 
replacement are cirrhosis (25.6%) biliary atresia 
(20.6'ro), primary biliary cirrhosis (17.2%), inborn 
errors of metabolism (13.0'ro), sclerosing cholangitis 
(8.1'70), and primary liver tumors (3.90/0). 
Donor-recipient matching. Recipients were select-
ed on the basis of medical need. estimated liver size and 
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Fig. 1. A, The: actuarial survival rate ror 520 patients and 667 first, scmnd, ;lnd third liver allo~raftsI B, 
.. \ctuanal IIraft survival rate for 517 pnmarv grafts and 150 retransplants. The: pnmarv graft survival rate IS 
significantly better than the survival rate for retransplanted grafts (p < 0,001), 
body weight, and ABO blood group. HLA typing and 
lymphocytotoxic crossmatching were done retrospec-
tively and played no role in recipient selection. The 
lymphocylOtoxic antibody crossmatch was done by the 
trypan blue dye exlusion method with reripient serum 
.lnd unfracliOnated donor lymphocytes at 37° C. Anti-
bodies in the recipient serum were detected with the 
same techniques, using a panel of lvmphocvtes 
obtained from 00 normal volunteers. PRA was derived 
from the results. If antibodies were present against 30 
of the 60 donors, the PRA was RM~o; if the reactivity 
was against 15 of the 60, the PRA was 25%, etc. 
RESULTS 
Patient and graft survival. The actuarial survival 
rate is 63.8% for the 520 patients at 2 vears and 48.2% 
for all 667 grafts at 2 years (Fig. I. A). The actuarial 
survival rate of primary grafts versus retransplants is 
shown in Fig. 1, B. Two hundred ninety-eight (57.6%) 
primary grafts and 53 (35.3%) retransplants are func-
tioning. The 2-year actuarial survival rate for pnmary 
grafts is 52.3% and 34.4% for retransplants. Primary 
graft survival is sigmficantlv better thm survival of 
retransplants (p < 0.00 I). 
Graft survival and PRA. The actuarial survival 
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Fig. 2. A. The actuarial survival rate for 505 grafts for which PRA data are available is compared with the 
survival rate for the entire series of 667 transplants. There is no significant difference:. B. The actuarial survival 
rate for 07 Ijrafts in pallents with a PRA ~reater than PM~oI including 39 grafts in patients with a PRA greater 
than bOo;.. compared with 438 grafts to pallents wllh a PRA less than 30'70. The:re: are: no significant differences in 
Ijraft surVival rates 
rates for 505 grafts (75.7%) for which PRA anal ysis is 
available are shown Fig. 2. A and are the same as 
survival rate for the entire series of 667 transplants. 
Sixty-seven patients had a PRA of 30% or more at 
transplantation including 39 patients with a PRA 
greater than 60"10. The 2-year graft survival rate in 
patients with a PRA under 30"10 is 48.9%, with a PRA 
of more than 30% is 51.4%, and with a PRA greater 
than 60% is 61.50/0 Eci~K 2, B). These survival rates are 
not significantly different. 
PRA dara are available for 417 (80.70/0) of the 517 
primary grafts and 88 (58.7"10) of the 150 retransplants. 
Fig. 3, A and C shows no difference in ~raft survival 
rates for the pnmarv ~rafrs or retransplants for which 
PRA data are available and the entire series of 517 
primary grafts and 150 retransplants. PRA was great-
er than 30% for transplantation of 48 primary grafts, 
including 31 patients with a PRA of more than SM~oK 
PRA was greater than 30% for 19 patients with 
retransplants. including eight patients with retrans-
plants with PRA greater than 60%. There are no 
significant differences in graft survival rates for pnma-
ry grafts (Fig. 3, B) or retransplants (Fig. 3, D) with 
high or low PRA. 
Graft survival and antibody crossmatch. :\nti-
body crossmatch data are available for 433 (649%) 
grafts that show no difference in survival from the 
complete senes of 667 grafts (Fig. 4, .-1). The 2-ve:lr 
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Fig. 3. There are no significant differences in actuarial survival rates for 417 primary grafts (A) and 88 
retransplants (C) for which PRA data are available compared with ail 517 primary grafts (A) and ail 150 
retransplants rC). There are no significant differences in graft survival rates for 48 primary grafts in pallents 
with a PRA greater than 30'. (B), includin~ 31 grafts in patients with a PRA greater than 60%, compared with 
369 primarv grafts in patients with a PRA under 30% (B) or for survival of 51 retransplants with a PRA greater 
than 30'. (D), including eight retransplants In patients with a PRA greater than 60'-, compared with 69 
rttransplants In patients with a PRA less than 30% (f)), 
survival rate for 62 grafts transplanted with a positive 
crossmatch is 55.8"10 and 49.8% for 371 grafts with a 
negative crossmatch (Fig. 4, 8). There is no statistical 
difference in graft survival rates for patients with 
positive and negative crossmatches at transplantation. 
There are no differences in graft survival rates for 
the 337 (65.2%) primary grafts (Fig. 5, A) or 96 
(64.0%) retransplants (Fig. 5, C) for which cross-
matches are available and the entire series of 517 
primarv grafts and 150 retransplants. Antibody cross-
match was positive for 38 (11.3%) of the 337 cross-
matched primary grafts and for 24 (25.0"70) of the 96 
crossmatched retransplants. There is no significant 
difference in graft survival between positive and nega-
tive crossmatched primary grafts (Fig. 5, B) or between 
positive and negative crossmatched retransplants (Fig. 
5, D). 
Among the 667 grafts were 382 (57.3"70) grafts for 
which both antibody crossmatch and PRA data are 
available. Fig. 6, A shows no signIficant difference in 
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Fig. 4. A, The actuarial survival rate for 433 grafts for which anribodv cross match data are available compared 
with the survival rail' for the enrir~ series of 667 transplanrs. There is no Sill;nttlcant di/Terence. B, Actu;lrIal 
survival for 62 II;rafts in pallenls with a positive crossmatch compared with 371 grafts in patients with a negallve 
crossmatch. There are no significant dtlTercnces In graft survtval rates. 
graft survival for these 382 grafts compared with the 
t'ntire series of 667 transplants. Twenty-eight trans-
plants were dont' in recipients with a positive donor 
antibody crossmatch and a current PRA of more than 
30%, including 20 patients with a PRA greater than 
60,0' There is no difference in graft survival rates for 
these high antibody, positive crossmatch transplants 
.1nd 305 grafts done with a negative cross match and 
PRA less than 30% (Fig. 6, B). 
Incidence of rejection and retrans plant at ion. 
\ntibody crossmatches were done in 53 of 78 patients 
In whom a graft was lost and retransplantation was 
done because of allograft rejection. The incidence of 
retransplantation for rejection of a graft with a positive 
('roSSmatch was seven of 62 grafts (11.3%) and with a 
negative crossmatch 46 (12.4'0) of 371 grafts. There is 
no significant difference between these rates of retrans-
plantation for rejection of crossmatch-positive and 
crossmatch-negative grafts. 
Renal transplantation after liver transplantation 
with a positive crossmatch. Five patients with chron-
ic liver and kidney failure have been given a renal 
allograft immediately after a liver transplant from the 
same donor. In two cases, the antidonor lymphocyte 
crossmatch was strongly positive immediately before 
liver transplantation. However, within a few hours 
:tfter implantation of the liver, repeat crossmalches 
could no longer detect significant levels of circulating 
preformed antidonor antibody. Renal allografts then 
implanted in these two patients functioned promptly 
and did not undergo hvperacute rejection. The postop-
erative course of one of these patients IS shown in Fig. 
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Fig. 5. There are no significant differences in actuarial survival rates for .337 primary grafts (A) and 96 
retransplants (C; for which crossmatch data are available compared with all 517 primary grafts (A) and all 150 
retransplants (C). There are no significant differences in graft survival rates for 38 primary grafts in patients 
with a positive crossmatch (B) compared with 299 primary grafts in patients with a negative crossmatch (B) or 
for survival of 24 retransplants with a positive crossmatch (D) compared wllh 72 retransplants in patients wilh a 
negative crossmalch ( D). 
7. All five patients continue to survive with functioning 
liver and renal allografts 2 weeks to 18 months after 
transplantation. 
DISCUSSION 
In a previous report on the results of liver transplan-
tation in 36 patients with a positive cytotoxic cross-
match: we used current recipient sera with fraction-
ated donor T-Iymphocytes assayed at 3r C. The 
results in the current series are based on crossmatches 
done with sera collected just before transplantation and 
unfractionated donor lymphocytes at 3r C by means 
of the trypan blue dye exclusion technique. In our 
laboratory's experience the results for this method 
correlate strongly with the assay using fractionated 
T-Iymphocytes at 370 C if kill of cells is complete. 
Therefore it is reasonable to believe that the positive 
crossmatches reponed here represent mostly preformed 
antibody to HLA antigens expressed ~n donor T-
lymphocytes. 
This study again confirms our previous observation 
that the liver allograft is not subject to hyperacute 
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Fig. 6. A, The actuarial survival rate for 382 grafts for which both antibody crossmatch and PRA data are 
available is compared with survival rate for the entire series of 667 transplants. There is no significant diffuence. 
B, The actuarial survival rate for 282 grafts in patients with a positive crossmatch and a PRA greater than 30'. 
(including 20 patients with a PRA more than 60".) is compared with survival [ate for 305 grafts in patients with 
a negative crossmatch and PRA less than 30.,. •. There are no significant differences in graft survival rates. 
rejection in the presence of preformed antidonor anti-
body and also shows that liver allograft survival as long 
as 2 years is not adversely affected by a positive 
antibody crossmatch for primary grafts or retrans-
plants. In funher contrast to events in renal transplan-
tation, a high panel-reactive antibodv at the time of 
liver transplantation is also not ~ssociated with 
decreased graft survival. 
The hyperacute rejection of renal allografts in 
patients who receive kidneys in the presence of pre-
formed antidonor antibodies has been well described. I·' 
Such grafts do not sustain an effective renal blood flow 
and angiography shows that the small vessels of the 
excised kidneys can be closed. Histopathologically, the 
arterioles and capillaries are plugged with formed 
blood elements, particularly erythrocytes and platelets. 
Our experience with combined liver-kidney transplan-
tation in two patients with a positive antibody cross-
match suggests that a liver allograft is able to clear or 
neutralize quickly sufficient circulating preformed 
antidonor antibody to permit transplantation of a renal 
allograft from the same donor without hyperacute 
rejection. Elucidation of the mechanism bv which the 
iiver allograft is able to inactivate or eliminate pre-
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Fig. 7. A 43-year-old woman with chronic livcr and renal failure from cnd-stage prlmarv biliar.' Cirrhosis 
received a liver transplant from a cadaver donor with whom she had a positive antibody crossmatch. A kidney 
was implanted from the same donor immediately after completion of the liver transplant. The postoperative 
(ourse. including immunosuppression with cyclosporine and prednisone. renal function. and livcr function. IS 
shown. Hyperacute rejcction of cither graft did not occur and both grafts continue to function wcll 18 months 
after transplantation. 
formed antibody may be important in developing 
clinical methods for the prevention or abrogation of 
hyperacute rejection in renal transplantation. 
The clinical circumstances of liver allograft loss are 
often complicated and the causes of graft loss are often 
multifactorial. Therefore it is difficult in the large and 
complex series of patients reported here to assess the 
relationship between antibody crossmatch and the 
incidence of graft loss from rejection. The best data are 
.1vailable for patients having retransplantation for 
rejection. since thorough examination of the removed 
graft is possible. We found that the incidence of 
retransplantation for rejection of a prior transplant 
with a negative or a positive crossmatch was not 
significantly different. 
In nearly every group of patients analyzed. survival 
was slightly better for grafts in patients with a positive 
antibody crossmatch or a high PRA at transplantation. 
However, this advantage in graft survival was not 
statistically significant in any case. Nevenheless, even 
in this large series of cases, less than 10"10 of the grafts 
were performed with a positive antibody crossmatch . 
and just 10"lo of the grafts involved recipients with a 
current PRA greater than 30"lo. It will require an even 
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larger experience to determine if preformed antibody 
has a significant protective or tolerogenic effect in liver 
transplantation. 
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DISCUSSION 
Dr. Folkert O. Belzer (Madison. Wis.). I had the 
opportunllY to revIew this manuscript a short llme al(o, and 
;u usual I stand in awe of the enormous rxpenence of the 
mittsbur~h group. 660 transplants in 520 p.ltIents. From 
what I hear thev are goin~ to be addin~ another 500 this 
year. 
When one Imens to this paper or reads the manuscript. it 
sounds as thou~h thiS group IS actuallv y1EFlalln~ a baSIC 
immunolollilc process. namelv. successful trJOSpiantallon 
against a posHlve ("vtotoxic T cell cross match and vet there 
must be an explanallon. 
I alwavs thoulliht a positive crossmatch muld be caused bv 
nonspectfic antlbodies and nOI alwavs b\" t.lIman Irukoc\·te 
J.ntigen (HLA) antibodies. All of these anllll<kltCS gr~ roxlC to 
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the organ, but the nonHLA antibodies will not produce an 
anamnestic response with the formation of more antibodies. 
Many years ago our Recorder, Dr. Turcotte, presented a 
series of kidney transplants that were performed against a 
positive crossmatch, and although many of those kidneys had 
early poor function, many survived. The explanation given 
was that these were probably B warm and not T warm 
antibodies. At that time we did not differentiate between 
Band T warm, but perhaps they were nonspecific anti-
bodies. 
Our Canadian colleagues have recently emphasized the 
importance of having a recent negative T cell crossmatch and 
that the historical positive cross match was unimportant. If all 
of these antibodies were HLA antibodies, even is positive 
historical crossmatch should have been important. 
Thus have you looked at those retransplants in which you 
could identify a specific HLA antibody such as an anti-
HLA-2 and then have transplanted that patient with a 
serond liver from a donor who had the HLA-2 antigen ~ 
What has happened to those livers? Have you also studied 
this in the laboratory where you could take a dog and 
transplant the kidney from another dog and allow the kidney 
to reject and then take the liver from the same donor and 
transplant it into the recipient dog? Did those livers func-
tion? 
Dr. Ronald M. FergU$On (Columbus, Ohio). Everyone in 
the transplant business is in awe of 660 liver transplants done 
in 4-years. Certainly for that the authors should be congrat-
ulated. Just reviewing that amount of data to make the 
presentation is an enormous effort. 
I think what the authors have done is to reconfirm and 
reaffirm existing policies in most centers. Because the logiS-
tics of donor procurement, donor-recipient matching with a 
prospective crossmatch is rather difficult in liver transplanta-
tion. so most centers are not prospectively doing it. As Dr. 
Belzer mentioned, I think most of us feel much more 
comfortable with this size of experience reaffirming our 
current policy. 
I have several specific questions about crossmatch policies 
at Pittsburgh and several theoretic questions. First, were 
these really all recent sera, immediately pretransplant sera, 
that the crossmatches were done on in those 62 positive 
patients, or were these sera from 2 weeks or a month before 
transplant? Second, were these T cell crossmatches, or were 
they on whole lymphocyte preparations from either the 
spleen or the lymph nodes? It makes a big difference. because 
dearly a positive warm B cell crossmatch has vcry little 
influence on the outcome of solid organ transplantation. The 
disastrous effects of hvperacute rejection are generally drrect-
ed at anllgens present on T cells and not on B cells. 
Third, do these patients wtth postlive crossmatches have a 
more "stormv" clinical course) Is there a hil!;her Incidence of 
acute aggressive rejection early after transplant tn these 
patients? 
Those are three clinical quesllons-now to some theorellc 
ones. First. whv would the vascular bed of the Itver be so 
different from rhat of the kidnev) If \"ou had preformed 
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cytotoxic complement-fixing antibody working a~allst donor 
antigens, they would bind to the endothelial bed or the liver, 
fix complement, activate the coagulation cascade, and cause 
immediate loss of function and clotting of that graft. but that 
does not happen in the liver. Does this have something to do 
with clearance of antibody binding to cenain cell types in the 
liver? Is there something about the fixed reticuloendothelial 
function of the liver that can eliminate this? What are your 
group's thoughts about this? 
Second, a theoretic question that I believe is most intrigu-
ing is that the best way to obtain a brisk antibody response is 
to perform plasmapheresis on a patient who has preexisting 
antibody to an antigen, present the antigen, and get an 
anamnestic response. So if the liver is acting as a sieve to 
acutely absorb a preexisting antibody, if it absorbs it out, 
there should be a strong anamnestic response once you 
present antigen in the form of the liver. 
You then might say that we are placing these patients on 
immunosuppression therapy. Certainly people have repeat-
edly tried with plasmapheresis and all types of immunosup-
pressants to eliminate positive crossmatches before kidney 
transplantation and have been unsuccessful. You use cyclos-
porine and prednisone. Of all the immunologic effects of 
cyclosporine, the one that does least well is blocking a 
secondary antibody response; in fact. experimentally it has 
hardly any effect on secondary antibody responses, so why 
once you acutely absorb antibody aren't these patients coming 
back strongly 7 days later with a brisk response of antibody 
and rejecting their liver? 
Third, in those patients with past positive crossmatches, 
the presence of anti-idiotypic antibody to the anti-HLA 
antibody that is formed in these individuals might be terribly 
important in downregulating the antibody response to that 
particular set of alloantigens on the donor graft. Have you 
looked back at the presence of idiOlypic antibody in these 
patients. for instance. like the group at Columbia IS doin~I 
,lOd does this playa role in modifying the adaptive Immune 
response to these grafts? 
Dr. Jeremiah G, Turcotte (Ann Arbor, Mich.). Dr. 
Gordon and the group from Pittsburgh are once agam to be 
complimented on a verv ImpreSSIve rlinical series. Six hun-
dred sixty-seven liver transplants within S\/:-year period is a 
remarkable achIevement. 
In both Ihe presentauon and the manuscript, strong 
("vidence is presented thaI the presence or absence of a 
positive donor-renpient crussmatch does not have a major 
Intluen('e on the outcome of liver transplantation. However. a 
word of cautIOn musl be interJected before these results are 
Interpreted to Indicate that a positIve crossmatch or a hH;h 
panel-reactive antlbod\' makes no difference 10 the outcome 
"I' liver tr:lOsplantatlon. With kidney transplantation. It was 
Illltiallv thought that ABO incompatlbilitv, liLA match 109, 
<lr the presence of a posltl\'e donor-reclpienl crossmatch made 
I'ltle dIfference. :ylthou~h it quicklv became apparent that 
.\BO incompatlbilitv and the donor-reciplC:nt crossmatch had 
,) major Impact on oUlcome. it took many years 10 demon-
I'! K~DK , \' K~ . 
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strate that HLA typing had a 5% to 15'0 inftuence 0 
long-term results. This is because so many variables IQa n 
influence survival of the graft or the patient; it will requir~ 
hundreds of patients to demonstrate differences in the range 
of 5'0 to 15'0. The problem could probably be best studied in 
the laboratory where most of the variables can be controlled, 
Nevenheless. the data presented is the best available and 
indicates that there is little or perhaps even no inftuence of 
the crossmatch or the presence of preformed antibody. 
Not only have the antibody data been presented, but this 
paper represents an update of the clinical results witll:livtr 
transplantation at Pittsburgh, which is by far the~t 
experience in the world. _ .. 
Dr. Peter J. Fabri (Columbus. Ohio). The liver is a vel' .. 
large organ in relative terms, and we are aware that i't 
requires at least 95'. destruction before we see many of the 
abnormalities that we call liver dysfunction. 
Although no one would argue that death is a very Specific 
marker of liver dysfunction. it is not a very sensitive one; and 
I wonder whether the authors have initiated any prospeaive 
evaluation of liver dysfunction so that they might be able to 
tell us whether there is a difference in these patients, even 
though they are still alive. 
Dr. Gordon (closing). Dr. Belzer has raised the question 
of the relevance of HLA matching in liver transplantation. 
During the past year we have reviewed the results for more 
than 500 consecutive liver transplant recipients treated with 
cyclosporine and prednisone to determine the relevance, if 
any, of ABO blood group matching, antibody crossmatch, 
and HLA matching to graft outcome. 
We recently reported to the Society of University Surgeons 
that ABO matching has a small but SIgnificant effect on 
primary graft survival. ABO-matched donor-recipient grafts 
fared better than ABO compatible but nonidentical or ABO 
incompatible grafts. We continue to recommend the use of 
ABO-matched grafts when practical. 
We have reported here that preformed antidonor antibody 
has no Significant effect on graft outcome. We are 'till in the 
process of analyzing the results for H LA matching so I do not 
yet know what our findings will be. Once our analysis of the 
HLA data is available. we will be in a position to reassess the 
question raIsed by Dr. Belzer about whether preformed 
antibodies to particular HLA speCIficities are relevant. 
Dr. Ferguson. the results we have reported today are 
~ssentially warm T ('ell crossmatches. Several vears a~o Dr. 
lwatsuki reported similar results for our tirst 174 grafts using 
nylon wool-fractloned donor Ivmphocvtes assayed with 
recipient serum al 37" \.. Our laboratorv statf is quite 
contident that Ihe results of this extended series. based on 
assays uSing unfr3ctlonaled donor Ivmphocvtes at 37' C, are 
essentiallv the same as that achieved with fractionated cells. 
We have routtnelv collected sera from all liver recipients JUSt 
before transplant3tton for hoth transplant~tlon antibody 
sludies and viral serolol1;y alld cultures. 
Dr. Ferl1;uson has asked why the kIdney is different from 
Ihe liver In liS vulnerabilitv to preformed antlbodv. I do not 
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have the answer, but some obvious differences come to mind. 
The kidney is designed to filter the blood and is mainly a 
capillary organ. Its microcirculation is vulnerable to clogging 
by platelets, ptoducts of coagulation, and other blood ele-
ments including antibody-coated erythrocytes. The liver is 
more complex in function, is mainly sinusoidal in architec-
ture. and is also a reticuloendothelial organ well equipped to 
clear potentially damaging elements from the circulation. 
II was also asked whether we have observed any difference 
in early or late graft function in these patients that might be 
related to preformed antibody. Early after transplantation, 
this is difficult to assess because of the complex clinical selling 
in which liver transplantation is performed. Variable degrees 
of liver dysfunction can be related to preservation injury, 
medical risk factors, technical problems with surgery, drugs, 
sepsis, or rejection. II is my impression, however, that 
patients with a positive antibody crossmatch do not have a 
Antibody crossmatch in liver transplantation 7 I 5 
stormier clinical course. Beyond 6 months after surgery, graft 
function. as assessed by traditional laboratory profiles. is 
remarkably stable in most patients. Subtle differences in graft 
function would require special testing and probably are of no 
real significance. However, graft loss is an easily identified 
end point and has the greatest significance to the patient. 
The data presented here suggest the possibilitv that 
preformed antibody may actually be protective of the liver 
allograft Does antibody coat antigen presenting cells in the 
liver and inhibit antigen processing? Why is there no 
rebound phenomenon such as Dr. ferguson has 5u'lgested? 
An even larger series of patients will be needed to determine 
if, in fact, preformed antibody is protective in clinical liver 
transplantation. As each of the discussants has suggested. 
laboratory investigation is necessary to unravel mecha-
nisms. 
La compatibilidad de aoticuerpos eo el traosplaote de higado 
Se revisaron 667 primero, segundo, y tercer aloinjertos en 520 pacientes con elobjeto 
de determinar el eJecto del anticuerpo reactivo "panel" del receptor (PRA) y 
compatlbilidad CTUzada de anticuerpos donador-receptor en un estudio ados anos de 
supervwencia de pacientes e inJertos hepaticos. N.J se encontro asociacion con 
disminucion de la supervivencia de pacientes 0 de injertos hepaticos en los injertos 
primarios 0 secundarios (retransplantes) ni relacion con compatibilidad cruzada 
POSIt iva para anticuerpo donador especifico preJormado, ni para anticuerpo reactivo. 
Dos pacientes han recibido transplantes renales despues de un injerto hepatico de un 
donador con el waf cada paciente tenia una prueba de compatibilidad cruzada de 
anticuerpos donador especifico fuertemente positiva. Ef higado, aparentemente elimino 
o neutralizo los anticuerpos antl-donador puesto que los aloinJertos renales empezaran 
a junclanar de mmediato y no suJrieron rechaza hiperagudo. 
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